Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3)
AssigneesThe Board of Trustees of the Leland Stanford Junior University, The United States Government as represented by the Department of Veterans Affairs
InventorsAnton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul A. Villeda
Life of this patent
Estimating the term…
Abstract
Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
Claims25
A method of reducing the effects of aging-associated impairment of neurogenesis in an adult mammal having the aging-associated impairment of neurogenesis, the method comprising:
- modulating C—C chemokine receptor type 3 (CCR3) in the adult mammal in a manner sufficient to reduce the effects in the adult mammal of the aging-associated impairment of neurogenesis.
Dependencies are inferred from the claim text.